NCT00701649View on ClinicalTrials.gov

Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

November 30, 2009

Conditions
Hypertension
Interventions
BIOLOGICAL

CYT006-AngQb

s.c.

BIOLOGICAL

Placebo

s.c.

Trial Locations (6)

D-68167

CRS Mannheim, Mannheim

D-41061

CRS Mönchengladbach, Mönchengladbach

CH-4031

University Hospital Basel, Basel

CH-3010

Inselspital, Bern

CH-1211

Hopital Universitaire Geneve, Geneva

CH-8091

Med Zentrum Römerhof, Zurich

Sponsors
All Listed Sponsors
lead

Cytos Biotechnology AG

INDUSTRY